Osmol Therapeutics

Despite decades of progress in oncology, the rate of chronic painful chemotherapy-induced peripheral neuropathy (CIPN) hasn’t budged.   A new global meta-analysis published in American Society of Regional Anesthesia and Pain Medicine (D’Souza et al., 2025) found that over 40% of patients with CIPN develop chronic pain, a number that’s remained stubbornly high for more than 20 years.   We’re grateful that the researchers are shining a light on this challenge, and we remain motivated to prevent CIPN and chemotherapy-induced cognitive impairment (CICI) before they start as we advance OSM-0205 into the clinic.

Congrats to Teresa Bitetti, a valued member of Osmol's Board, on her recent appointment to the Board of Directors at Aura Biosciences.   Teresa has been instrumental in shaping Osmol's strategic direction and commitment to addressing cancer patients' unmet needs, bringing sharp strategy and global impact—Aura is lucky to have her.

Find us at #VentureConnect2025 this week! Join our CEO, Bob Linke, as he presents during the Biopharma Track tomorrow, March 26, from 10:00 - 11:15 AM ET. Bob will share insights into our lead candidate, OSM-0205, and its potential to address chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI). Looking forward to connecting with fellow industry leaders at this important event. Learn more: https://bit.ly/423F5Bm

Currently, no alternative treatments have been approved for CIPN or CICI. Our lead candidate, OSM-0205, with a single IV dose 30 minutes before a taxane-based chemotherapy infusion, may prevent chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI) before they start. We're headed to the clinic soon to advance our Phase 1 clinical study. Replay is now available for #BiotechShowcase 2025, as presented by our CEO, Bob Linke: https://bit.ly/3FpqwjX

According to this article in Inside Precision Medicine, patients who experience painful CIPN symptoms often face significant limitations in their daily lives, a worse quality of life, and financial struggles. In addition, treatment outcomes and survival rates can be impacted when chemotherapy is reduced or discontinued entirely as a result of severe cases.   At Osmol, we believe patients shouldn’t have to choose between effective cancer treatment and their long-term quality of life. That’s why we’re working to prevent CIPN before it starts, allowing patients to focus on recovery—not lasting side effects.   Read the full article here: https://bit.ly/3Dt1YpB

DYKT Black breast cancer survivors may be disproportionately affected by chemotherapy-induced peripheral neuropathy (CIPN)? Learn about the research via Oncology Nursing News, which sheds light on how racial disparities in cancer care can leave lasting impacts on survivors. At Osmol, our work focuses on prevention, aiming to stop CIPN before it starts so patients can focus on recovery, not side effects. Read the full article: https://bit.ly/4htGtDO

Cancer treatment saves lives, but for many survivors, the journey doesn’t end when treatment stops. According to American Association for Cancer Research, 18 million cancer survivors in the U.S. are living with, through, and beyond their disease. For many, chemotherapy-induced peripheral neuropathy (CIPN) remains a debilitating, life-long side effect—impacting mobility, daily activities, and overall well-being. At Osmol, we are committed to preventing the overlooked challenges of cancer treatment. Our groundbreaking approach targets CIPN and chemotherapy-induced cognitive impairment (CICI), commonly associated with taxane-based chemotherapies, so patients don’t have to choose between treatment success and quality of life. This National Cancer Prevention Month, we also recognize the strength of survivors. By addressing the lasting effects of chemotherapy, we can improve outcomes and ensure that more patients thrive beyond their diagnosis. Learn how OSM-0205 is striving to address this critical challenge in cancer care: https://bit.ly/3WVNXaj

ICYMI: #BiotechShowcase 2025 presentation – webcast now available! Listen in as our CEO, Bob Linke, shares the groundbreaking potential of OSM-0205, a first-in-class treatment for chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI), in hopes of easing the journey for cancer patients. Webcast will be available for six months: https://bit.ly/4hj6ANb

✋ Who's headed to #NEXUS2025 in San Francisco for the week? 🗣️ Don't miss Bob Linke, CEO, as he discusses how OSM-0205's first-in-class mechanism is paving the way for improved patient outcomes by addressing chemotherapy-induced side effects like chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI). We're proud to contribute to these critical conversations to enhance patients' lives. Don't miss tomorrow's presentation during the Biopharma Track. https://bit.ly/426V6bi Blinkpad #JPMHealthcareWeek

We’re headed to #NEXUS2025 – a gathering of innovators, investors, and thought leaders shaping the future of healthcare. Our CEO, Bob Linke, will present during the Biopharma Track on Tuesday, January 14, in South San Fran. Bob will spotlight OSM-0205, our lead candidate, and its potential to transform cancer care by addressing chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI). Learn more and register here: https://bit.ly/426V6bi #JPMHealthcareWeek MT Blinkpad